Falette N, Paperin M P, Treilleux I, Gratadour A C, Peloux N, Mignotte H, Tooke N, Löfman E, Inganäs M, Bremond A, Ozturk M, Puisieux A
Unité d'Oncologie Moléculaire, Unité INSERM U453, Centre Léon Bérard, Lyon, France.
Cancer Res. 1998 Apr 1;58(7):1451-5.
The most important subgroup of breast cancer patients for which reliable prognostic factors are needed are women without axillary lymph node involvement. Although overall, these patients have a good prognosis, it is known that 20-30% will experience a recurrence of the disease. To determine the prognostic significance of P53 tumor suppressor gene mutation, specimens from 113 primary breast cancers were evaluated for the presence of P53 alterations, as detected by cDNA sequencing of the entire coding sequence of the gene. The median follow-up for patients was 105 months. P53 gene mutation was an independent prognostic marker of early relapse and death. Our results suggest that P53 gene mutations could be an important factor to identify node-negative patients who have a poor prognosis in the absence of adjuvant therapy. Prospective studies should be designed to determine which therapy should be performed in this subgroup of patients.
对于乳腺癌患者而言,最需要可靠预后因素的亚组是那些无腋窝淋巴结受累的女性。总体而言,这些患者预后良好,但已知有20% - 30%的患者会出现疾病复发。为了确定P53肿瘤抑制基因突变的预后意义,对113例原发性乳腺癌标本进行了评估,通过对该基因整个编码序列进行cDNA测序来检测P53改变的存在情况。患者的中位随访时间为105个月。P53基因突变是早期复发和死亡的独立预后标志物。我们的结果表明,P53基因突变可能是识别在无辅助治疗情况下预后不良的淋巴结阴性患者的一个重要因素。应设计前瞻性研究以确定该亚组患者应采用何种治疗方法。